Literature DB >> 8001365

Effects of treatment with the 21-aminosteroid, U7438F, on pulmonary cytokine expression following hemorrhage and resuscitation.

R Shenkar1, E Abraham.   

Abstract

OBJECTIVE: To determine the effects of therapy with the antioxidant 21-aminosteroid, U74389F, on cytokine mRNA levels following hemorrhage and resuscitation.
DESIGN: Prospective, controlled animal study.
SETTING: University research laboratory.
SUBJECTS: Male bronchoalveolar lavage B/c (BALB/c) mice.
INTERVENTIONS: U74389F (10 mg/kg) in CS4 vehicle or CS4 vehicle alone, was administered intravenously to bronchoalveolar lavage B/c mice 15 mins before 30% blood volume hemorrhage, with resuscitation 60 mins later.
MEASUREMENTS AND MAIN RESULTS: Semiquantitative polymerase chain reactions were used to determine the effects of therapy with U74389F on cytokine mRNA levels among intraparenchymal pulmonary mononuclear cells, alveolar macrophages, and peripheral blood mononuclear cells obtained 2 hrs and 3 days after hemorrhage. In mice treated with U74389F, mRNA levels for interleukin (IL)-1 beta, IL-6, IL-10, tumor necrosis factor-alpha, and interferon-gamma were significantly decreased among intraparenchymal pulmonary mononuclear cells obtained 3 days, but not 2 hrs, after hemorrhage. No effects of therapy with U74389F were found in modulating posthemorrhage cytokine expression among alveolar macrophages or peripheral blood mononuclear cells.
CONCLUSIONS: These studies demonstrate that treatment with U74389F, a 21-aminosteroid whose major activity is inhibition of lipid peroxidation due to the generation of reactive oxygen intermediates, significantly decreases hemorrhage-induced activation of proinflammatory cytokine expression among pulmonary cell populations. In addition, the present results, showing decreased expression of proinflammatory and immunoregulatory cytokines among intraparenchymal pulmonary mononuclear cells following treatment with U74389F, suggest that 21-aminosteroids may have clinical utility in preventing and/or modulating acute lung injury in the postinjury period.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8001365     DOI: 10.1097/00003246-199501000-00022

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

1.  Comparison of various lazaroid compounds for protection against ischemic liver injury.

Authors:  N Ishizaki; Y Zhu; S Zhang; A Nemoto; Y Kobayashi; V M Subbotin; R G Lee; T E Starzl; S Todo
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

2.  The effects of lazaroid U-74389G in a rat sepsis model.

Authors:  Yun-Te Chang; Shue-Ren Wann; Kai-Hseng Hsieh; Yung-Ching Liu; Ching-Hsiung Chang; Mu-Shun Huang; Chun-I Huang; Hong-Tai Chang
Journal:  Inflamm Res       Date:  2010-07-11       Impact factor: 4.575

Review 3.  Antioxidant pharmacological therapies for COPD.

Authors:  Irfan Rahman; William MacNee
Journal:  Curr Opin Pharmacol       Date:  2012-02-18       Impact factor: 5.547

Review 4.  Pharmacological antioxidant strategies as therapeutic interventions for COPD.

Authors:  Irfan Rahman
Journal:  Biochim Biophys Acta       Date:  2011-11-09

5.  Regulation of ICAM-1 expression in mouse macrophages.

Authors:  A K Hubbard; C Giardina
Journal:  Inflammation       Date:  2000-04       Impact factor: 4.092

6.  Comparison of various lazaroid compounds for protection against ischemic liver injury.

Authors:  N Ishizaki; Y Zhu; S Zhang; A Nemoto; Y Kobayashi; V Subbotin; T E Starzl; S Todo
Journal:  Transplantation       Date:  1997-01-27       Impact factor: 4.939

7.  21-aminosteroids prevent the down-regulation of hepatic cytochrome P450 induced by hypoxia and inflammation in conscious rabbits.

Authors:  A Galal; P Souich
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

8.  Lazaroid U-74389G for 48-hour canine liver preservation.

Authors:  S Todo; N Hamada; Y Zhu; S Zhang; V Subbotin; A Nemoto; I Takeyoshi; T E Starzl
Journal:  Transplantation       Date:  1996-01-27       Impact factor: 4.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.